Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Primary Immunodeficiency
Interventions: IGSC 20%; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more

Conditions: Advanced Non CNS Tumors
Interventions: Talimogene Laherparepvec; Drug
Lead sponsor: Amgen; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 9
States / cities: Wilmington, Delaware • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: DCI 1020; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: Up to 2 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Healthy
Interventions: cefdinir (Omnicef), amoxicillin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 8 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 3
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio

Conditions: Lupus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more

Conditions: Multiple Myeloma
Interventions: Fluphenazine HCl; Drug
Lead sponsor: Immune Control; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Lung Cancer, Non-Small Cell
Interventions: Pazopanib (GW786034); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fort Myers, Florida • Orlando, Florida + 10 more

Conditions: Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: Lawrenceville, New Jersey

Conditions: Multiple Myeloma
Interventions: Structural Image, Functional Image, Digit Span subtest, Brief Test of Attention, Trail Making Test (Parts A & B), Auditory Consonant Trigrams Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, The Center for Epidemiological Study-Depression, The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4, Blood draw; Diagnostic Test · Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Rosacea
Interventions: Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1%, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions: Edoxaban, Standard of Care; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Day to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Adipose Derived Stem Cells; Other
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Sunrise, Florida

Conditions: Osteoarthritis
Interventions: Global® AP™ Total shoulder arthroplasty; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Phoenix, Arizona • Asheville, North Carolina • Cincinnati, Ohio + 1 more

Conditions: Bacterial Infections, Eye Infections, Cataract Extraction
Interventions: AzaSite Eye Drops, Vigamox Eye Drops; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 21 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more

Conditions: Cervical Deformity
Interventions: Surgical intervention; Procedure
Lead sponsor: International Spine Study Group Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 16
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 11 more

Conditions: Pelvic Metastasis
Interventions: Photodynamic nails; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Injuries, Traumatic
Interventions: Goal-Oriented Attentional Self-Regulation (GOALS), Brain Health Education (BHE), fMRI; Behavioral · Other · Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplant; Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimer's Disease
Interventions: MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more

Conditions: Glioblastoma or Gliosarcoma
Interventions: Single intratumoral injection of DNX-2401, Interferon-gamma; Drug
Lead sponsor: DNAtrix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more

Conditions: Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions: LY4405094, Placebo, Florbetapir F18, Florbetaben F 18; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anaheim, California • Irvine, California • Los Alamitos, California + 10 more

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Search by objective public record fields.

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation

A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Adipose Derived Cells for Chronic Obstructive Pulmonary Disease

Global® AP™ Total Shoulder Arthroplasty

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Mild TBI Assessment & Rehabilitation

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC